| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee602c630e57f59c6cfc1c1634e36064 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
1997-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2000-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3d81bbe7724d7e34c820509575c6682
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8f2fb712ab3b18e8b92a595f7f9f365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_369f161c1fc9b0a1cc5c8e8836753714
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d33a99cd30d3047790ee4e90ab3c76b4 |
| publicationDate |
2000-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6080910-A |
| titleOfInvention |
Transgenic knockout animals lacking IgG3 |
| abstract |
The present invention provides non-human transgenic animals in which an antibody subtype is selectively inactivated such that the transgenic animals express a reduced level of IgG3 relative to the levels expressed by the corresponding wild-type animal. Selective inactivation is achieved by the disruption through homologous recombination of the a nucleic acid sequence which encodes a constant region in the antibody subtype. The present invention provides transgenic animals which contain a disrupted Cγ3 gene. These transgenic animals retain the ability to express other antibody isotypes and subtypes. The present invention further provides methods for using these transgenic animals for screening candidate therapeutic compounds and for producing monoclonal antibodies which contain reduced levels of IgG3. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019006330-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011145937-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10881085-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015197557-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8754287-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9888675-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002162131-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11234419-B2 |
| priorityDate |
1997-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |